*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation…
ceceSeptember 7, 2021